PSCA hFc Chimera, Human

PSCA hFc Chimera, Human

Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
Z05771
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc PSCA (Leu12-Ser86)_x000D_
Accession # O43653
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized PSCA hFc Chimera, Human at 2μg/ml (100μl/Well) on the plate can bind Biotinylated Anti­PSCA Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 34.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer.
Synonyms PSCA; UNQ206; PRO232

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.